Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.

Antiviral research - 1 Nov 2008

Kobayashi Masanori, Nakahara Koichiro, Seki Takahiro, Miki Shigeru, Kawauchi Shinobu, Suyama Akemi, Wakasa-Morimoto Chiaki, Kodama Makoto, Endoh Takeshi, Oosugi Eiichi, Matsushita Yoshihiro, Murai Hitoshi, Fujishita Toshio, Yoshinaga Tomokazu, Garvey Edward, Foster Scott, Underwood Mark, Johns Brian, Sato Akihiko, Fujiwara Tamio

Abstract excerpt

Resistance passage studies were conducted with five INIs (integrase inhibitors) that have been tested in clinical trials to date: a new naphthyridinone-type INI S/GSK-364735, raltegravir, elvitegravir, L-870,810 and S-1360. In establishing the passage system and starting from concentrations several fold above the EC(50) value, resistance mutations against S-1360 and related diketoacid-type compounds could be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Evaluation, Preclinical
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HeLa Cells

Share to HIV Infections

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to T-Lymphocytes

Source

Identifiers

PMID: 18625269
DOI: 10.1016/j.antiviral.2008.06.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.PMID 18625269Read ↗

Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments.Semantic proximity Read ↗

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.Semantic proximity Read ↗

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor DolutegravirSemantic proximity Read ↗

Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses.Semantic proximity Read ↗

Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.Semantic proximity Read ↗

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.Semantic proximity Read ↗

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance SubstitutionsSemantic proximity Read ↗

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.Semantic proximity Read ↗

Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.Semantic proximity Read ↗

Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.Semantic proximity Read ↗

4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.Semantic proximity Read ↗

In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.